The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
Last updated
Peptide Profile

Sibutramine: Research, Dosing, and Where to Buy in 2026

A research-first profile for Sibutramine, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.

⚕️ US PRESCRIPTION REQUIRED. Sibutramine is a prescription medication in the United States. Prescription and controlled-substance rules differ by country, so check your local laws before any purchase or use. Information on this page is educational and not medical advice. Consult a licensed prescribing physician.
Quick Answer

Sibutramine is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Sibutramine, each linked to its source.

Key Facts
Pharmaceutical
  • 0 aggregated dosing-protocol mentions from source transcripts.
  • 8 PubMed-indexed citations listed in the research table below.
  • 0 vendor recommendations captured from named experts.
Sourced to expert
Check vendor COA
Verify dose w/ clinician

What is Sibutramine?

Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.

Sibutramine Dosing Protocols

The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.

No transcript-derived dosing mentions in current source set.

Where to Buy Sibutramine in 2026

No tracked vendor recommendations for Sibutramine yet. See our vendor directory.

Side Effects and Safety

Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.

User Reviews

User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.

Research Efficacy Snapshot

Published efficacy percentages cited in PubMed trials and named-expert reports about Sibutramine. Each line links to the original source.

  • "Weight loss of > 1% within the first month of treatment appears indicative of good long term response with sibutramine." · McNeely W et al, 1998 PubMed
  • "Up to 15% of patients in < or = 6-month studies did not respond to treatment irrespective of dose." · McNeely W et al, 1998 PubMed
  • "By six months, 69% of patients treated with sibutramine 15 mg achieve a 5% or greater reduction in their baseline weight." · Lean M et al, 1997 PubMed
  • "In controlled studies, 84% of sibutramine-treated patients reported adverse events, compared with 71% of patients receiving placebo." · Lean M et al, 1997 PubMed
  • "Sibutramine also stimulates thermogenesis in rats, producing sustained (> 6 h) increases in oxygen consumption of up to 30%." · Stock M et al, 1997 PubMed

Research and Studies

8 PubMed-indexed papers reference Sibutramine. Top 8 shown.

Frequently Asked Questions

Is Sibutramine FDA-approved?

Sibutramine is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.

How much research has been published on Sibutramine?

8 PubMed-indexed paper(s) reference Sibutramine in our current research feed. See the Research and Studies section above for citations.